Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB-0998 for Guillain-Barré Syndrome
NCT02342184Phase 3Completed
- Sponsor
- Japan Blood Products Organization
- Start
- Aug 2014
- Primary completion
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of immune globulin in Guillain-Barré syndrome (GBS), sponsored by Japan Blood Products Organization. Primary endpoint: Proportion of patients with more than 1 grade improvement in Hughes Functional Grade (FG) at 4 weeks. Started Aug 2014; status: completed.
02
Drugs
immune globulin
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NCT02342184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342184.